{"transactions":[{"id":725518,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":35156,"kind":"person","name":"Thomas John Charles","position":1,"cik":"0002114900","reported_name":"Thomas John Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T22:45:51.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest ratably over a four-year period beginning on February 28, 2026."}],"balance_after":6500,"derivative":{"exercise_price":179.25,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0002114900-26-000009","document":"wk-form4_1782513949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000211490026000009/wk-form4_1782513949.xml","form_type":"4"}},{"id":725517,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":35156,"kind":"person","name":"Thomas John Charles","position":1,"cik":"0002114900","reported_name":"Thomas John Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-06-26T22:45:51.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":347.27,"value":347270.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002114900-26-000009","document":"wk-form4_1782513949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000211490026000009/wk-form4_1782513949.xml","form_type":"4"}},{"id":725516,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":35156,"kind":"person","name":"Thomas John Charles","position":1,"cik":"0002114900","reported_name":"Thomas John Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-06-26T22:45:51.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":179.25,"value":179250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0002114900-26-000009","document":"wk-form4_1782513949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000211490026000009/wk-form4_1782513949.xml","form_type":"4"}},{"id":761860,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":35156,"kind":"person","name":"Thomas John Charles","position":1,"cik":"0002114900","reported_name":"Thomas John Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-05-27T21:17:56.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":642,"price":302.03,"value":193903.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. The Rule 10b5-1 trading plan will terminate on December 31, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002114900-26-000006","document":"wk-form4_1779916673.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711279/000211490026000006/wk-form4_1779916673.xml","form_type":"4"}}]}